Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
K
041960
vs
K
KOSPI 200
Over the past 12 months, Komipharm International Co Ltd has underperformed KOSPI 200, delivering a return of +44% compared to KOSPI 200's +56% growth.
Stocks Performance
041960 vs KOSPI 200
Performance Gap
041960 vs KOSPI 200
Performance By Year
041960 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Komipharm International Co Ltd
Glance View
Komipharm International is a South Korean pharmaceutical company that develops and sells medicines and health products for animals, and also works in some human drug and biotech-related areas. Its business centers on making finished products such as veterinary drugs, drug ingredients, and other life-science products that help treat or prevent disease. The company makes money by selling these products to animal clinics, livestock and farm customers, and other healthcare or pharmaceutical buyers that need reliable drug supply. It may also earn income from related manufacturing and development work, depending on the product line and customer contract. What makes Komipharm’s business different is that it sits in the middle of the drug value chain: it is not just a distributor, but a developer and manufacturer. That means it must manage research, quality control, and regulated production, which are important in both animal health and pharmaceutical markets.